Transactions with shares and linked securities in Genmab

New Post Public Reply Private Reply Replies (0) Message Board
News Desk 2018
Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons

Company Announcement

Copenhagen, Denmark; August 18, 2016 – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation 2016/523, the persons below have given Genmab A/S (Nasdaq Copenhagen: GEN) power of attorney on their behalf to publish and report their trading in Genmab shares and related instruments, as follows:   

1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Jan van de Winkel
2. Reason for the notification
a) Position/status President & Chief Executive Officer
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant, auction platform, auctioneer or auction monitor
a) Name Genmab A/S
b) LEI-code N/A
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument   Identification code Share     DK0010272202
b) Nature of the transaction Sale of shares
c) Price(s) and volume(s) Price(s)

DKK 1,091.91

Volume(s)

100,000

d) Aggregated information -       - Aggregated volume - Price  
e) Date of the transaction 2016-08-18
f) -       Place of the transaction Nasdaq Copenhagen (XCSE and DCSE) BATS (BATE and BATD) CHI-X (CHIX and CHID) Turquoise (TRQX and TRQM)
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name David A. Eatwell
2. Reason for the notification
a) Position/status Executive Vice President & Chief Financial Officer
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant, auction platform, auctioneer or auction monitor
a) Name Genmab A/S
b) LEI-code N/A
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument   Identification code Share     DK0010272202
b) Nature of the transaction Sale of shares
c) Price(s) and volume(s) Price(s)

DKK 1,091.91

Volume(s)

40,000

d) Aggregated information -       - Aggregated volume - Price  
e) Date of the transaction 2016-08-18
f) -       Place of the transaction Nasdaq Copenhagen (XCSE and DCSE) BATS (BATE and BATD) CHI-X (CHIX and CHID) Turquoise (TRQX and TRQM)
1. Details of the person discharging managerial responsibilities / person closely associated
a) Name Anders Gersel Pedersen
2. Reason for the notification
a) Position/status Board member
b) Initial notification/Amendment Initial notification
3. Details of  the issuer,  emission  allowance  market participant, auction platform, auctioneer or auction monitor
a) Name Genmab A/S
b) LEI-code N/A
4. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted
a) Description of the financial instrument, type of instrument   Identification code Share     DK0010272202
b) Nature of the transaction Sale of shares
c) Price(s) and volume(s) Price(s)

DKK 1,091.91

Volume(s)

12,000

d) Aggregated information -       - Aggregated volume - Price  
e) Date of the transaction 2016-08-18
f) -       Place of the transaction Nasdaq Copenhagen (XCSE and DCSE) BATS (BATE and BATD) CHI-X (CHIX and CHID) Turquoise (TRQX and TRQM)

About Genmab Genmab is a publicly traded, international biotechnology company specializing in the creation and development of differentiated antibody therapeutics for the treatment of cancer.  Founded in 1999, the company has two approved antibodies, Arzerra® (ofatumumab) for the treatment of certain chronic lymphocytic leukemia indications and DARZALEX® (daratumumab) for the treatment of heavily pretreated or double refractory multiple myeloma. Daratumumab is in clinical development for additional multiple myeloma indications and for non-Hodgkin’s lymphoma. Genmab also has a broad clinical and pre-clinical product pipeline.  Genmab's technology base consists of validated and proprietary next generation antibody technologies - the DuoBody® platform for generation of bispecific antibodies, and the HexaBody® platform which creates effector function enhanced antibodies.  The company intends to leverage these technologies to create opportunities for full or co-ownership of future products. Genmab has alliances with top tier pharmaceutical and biotechnology companies.  For more information visit www.genmab.com .  

Contact:           Rachel Curtis Gravesen, Senior Vice President, Investor Relations & Communications T: +45 33 44 77 20; M: +45 25 12 62 60; E: r.gravesen@genmab.com

This Company Announcement contains forward looking statements. The words “believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions identify forward looking statements. Actual results or performance may differ materially from any future results or performance expressed or implied by such statements. The important factors that could cause our actual results or performance to differ materially include, among others, risks associated with pre-clinical and clinical development of products, uncertainties related to the outcome and conduct of clinical trials including unforeseen safety issues, uncertainties related to product manufacturing, the lack of market acceptance of our products, our inability to manage growth, the competitive environment in relation to our business area and markets, our inability to attract and retain suitably qualified personnel, the unenforceability or lack of protection of our patents and proprietary rights, our relationships with affiliated entities, changes and developments in technology which may render our products obsolete, and other factors. For a further discussion of these risks, please refer to the risk management sections in Genmab’s most recent financial reports, which are available on www.genmab.com . Genmab does not undertake any obligation to update or revise forward looking statements in this Company Announcement nor to confirm such statements in relation to actual results, unless required by law.

Genmab A/S and its subsidiaries own the following trademarks: Genmab ® ; the Y-shaped Genmab logo ® ; Genmab in combination with the Y-shaped Genmab logo™; the DuoBody logo ® ; the HexaBody logo™; HuMax ® ; HuMax-CD20 ® ; DuoBody ® ; HexaBody ® and UniBody ® . Arzerra ® is a trademark of Novartis AG or its affiliates. DARZALEX ® is a trademark of Janssen Biotech, Inc.

Company Announcement no. 37 CVR no. 2102 3884

Genmab A/S Bredgade 34E 1260 Copenhagen K Denmark

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lake Ridge's Strong Quarter Meets a Book Value Hit

Updated Category News Views 105

An $8.25-per-share securities markdown is the splinter in an otherwise sturdy third-quarter report from Lake Ridge Bancorp. The bank earned $9.8 million, or $4.97 per common share, for the quarter ended September 30, 2026. That is up from $9.0 million, or $4.59 per share, in the prior quarter and $7.7 million, or $3.94 per share, a year earlier. Those are not flimsy...

Continue Reading
AMPERA Joins Berto to Power Future Energy Innovations

Updated Category News Views 205

The Power Play You Didn't See Coming AMPERA and Berto just made a move that could stir up some serious waves in the energy sector. They've inked a business combination deal set to push advanced energy technology to the forefront. With AMPERA's valuation clocking in at roughly $900 million, this partnership aims to bring cutting-edge power solutions from concept to market....

Continue Reading
TYYY Liquidation Leaves Holders With a Tight Exit Window

Updated Category News Views 210

A fund can vanish faster than investors can read the fine print, and TYYY is doing exactly that. Exchange Traded Concepts has approved the closure and liquidation of the xETFs TSLA Daily Income ETF, with the fund expected to cease operations and distribute cash on or about November 20, 2026. This is not a debate about whether holders should love or hate Tesla. The product...

Continue Reading
Three Cash Buyouts Draw Fresh Shareholder Scrutiny

Updated Category News Views 135

Three cash-price tags landed on the tape with a lawyerly asterisk attached: are public holders actually getting a fair shake? On November 18, 2026, Halper Sadeh LLC said it was investigating proposed sales involving Surgery Partners, Braze and CCC Intelligent Solutions. That is not a finding of misconduct, and investors ought to keep that distinction bolted firmly to the...

Continue Reading
Google Search Data Sharing Faces a Privacy Reality Check

Updated Category News Views 58

Search queries are messy little confessions, and that is exactly why this case deserves more than a bureaucratic shrug. Woodway Assurance's independent assessment says Google's search-query data could be treated as anonymized for sharing under the Digital Markets Act, but only if the European Commission tightens parts of its July 2026 framework. That is not a clean bill...

Continue Reading
Philadelphia Firm Targets 100 Toys for Children This Holiday

Updated Category News Views 181

A hundred unopened toys can look modest on paper, yet that is exactly why this Philadelphia effort lands differently than the usual chest-thumping corporate charity chatter. van der Veen, Hartshorn & Levin has set a clear holiday target: collect 100 new, unwrapped toys for children in the Philadelphia area through the U.S. Marine Corps Reserve Toys for Tots program. No...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
RayNeo's Black Friday Push Tests Smart Glasses Demand

Updated Category News Views 22

A million shipped pairs is a real milestone, but holiday markdowns are where the rubber meets the road for RayNeo. The company is taking its XR gaming glasses and iO AI smart glasses into Europe’s Black Friday scrum with discounts running through late November, betting that portability, giant virtual screens and a little AI convenience can pry open consumers’ wallets....

Continue Reading
LifeVac's 7,000 Reported Saves Deserve Careful Context

Updated Category News Views 156

Veggie straws are supposed to be harmless until they are not. LifeVac says a 19-month-old girl in South Dakota became unable to breathe on November 14 after eating the snack, with a sticky piece creating a complete airway obstruction. Her father retrieved the family's LifeVac, used the pediatric mask while she was on her back, and the company says one application...

Continue Reading
Humanoid Robots Need Results Before 2035 Hype Peaks

Updated Category News Views 178

A robot climbing stairs is neat; a robot finishing Tuesday’s shift is the investment case. The latest humanoid robotics forecast puts the global market at $3.07 billion in 2026, up from $2.26 billion in 2025, and projects $47.49 billion by 2035. That is a 35.59% compound annual growth rate, the kind of number that makes investors sit up straight. It also demands a...

Continue Reading

Top 5 Most Recently Viewed Articles

Streamlined Shipping Solutions for UK Businesses by Wix.com

Updated Category News Views 279

Enhancing Shipping for UK Businesses with Wix.com Wix.com Ltd. (NASDAQ: WIX) has taken a significant step forward in supporting UK businesses by integrating Royal Mail within its innovative Wix Shipping platform. This breakthrough means that merchants can now easily transition from traditional, manual shipping processes to a fully automated system, streamlining their...

Continue Reading
FullFlex.Agency Innovation: AI Solutions for Business Growth

Updated Category News Views 147

FullFlex.Agency Unleashes Innovative Marketing Solutions FullFlex.Agency is celebrating its continued success as it enters the fourth quarter of its second year. This dynamic organization, known for its robust AI-powered marketing solutions and transparent pricing structures, emphasizes its commitment to helping businesses thrive across various sectors. Expansion of...

Continue Reading
NexBank Achieves Recognition as Leading Mortgage Lender

Updated Category News Views 207

NexBank: A Consistent Leader in Mortgage Lending NexBank has once again made headlines by being recognized as one of the top mortgage lenders in the nation for the fourth consecutive year. This achievement underscores the bank's ongoing commitment to excellence in the mortgage industry. The latest rankings show that NexBank secured the 12th position for Correspondent...

Continue Reading
First Mining Gold Corp. Strengthens Position with First Majestic

Updated Category News Views 173

Key Agreement Enhancements Between First Mining Gold and First Majestic First Mining Gold Corp. (TSX: FF) has announced an important agreement with First Majestic Silver Corp. that is expected to positively impact its financial position and operational strategy. This mutually beneficial arrangement revises the parameters of the existing silver purchase agreement,...

Continue Reading
Expert Weighs In: College Apps Need Strategy, Not Count

Updated Category News Views 38

A Lesson for College-Bound Families When the question comes up about college applications, you expect to hear numbers thrown around like eight, twelve, or even twenty. But the idea that there's some magic number to crack the admissions code? It just doesn't hold water. Instead, it's all about the risk baked into your list of schools. That's where HelloCollege's recent...

Continue Reading